| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $19,119 | 1 | 100 |
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $19,119 | $-19,119 |
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk …
Over the last 12 months, insiders at Geron Corporation have bought $0 and sold $19,119 worth of Geron Corporation stock.
On average, over the past 5 years, insiders at Geron Corporation have bought $125,972 and sold $5.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 13,300 shares for transaction amount of $15,667 was made by LAWLIS V BRYAN (director) on 2025‑05‑09.
| 2026-02-18 | Sale | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | 9,855 0.0015% | $1.94 | $19,119 | -26.80% | |
| 2025-05-09 | LAWLIS V BRYAN | director | 13,300 0.0021% | $1.18 | $15,667 | +16.95% | ||
| 2025-02-27 | Ziegler James | EVP, Chief Commercial Officer | 100,000 0.0148% | $1.60 | $160,000 | -21.26% | ||
| 2025-02-27 | Samuels Scott Alan | EVP, Chief Legal Officer | 15,000 0.0022% | $1.61 | $24,150 | -21.26% | ||
| 2025-02-27 | SCARLETT JOHN A | Chairman, President and CEO | 12,500 0.002% | $1.76 | $22,063 | -21.26% | ||
| 2024-07-08 | Sale | GRETHLEIN ANDREW J | EVP, Chief Operating Officer | 674,348 0.1164% | $4.56 | $3.07M | -26.16% | |
| 2024-06-10 | Sale | Kapur Anil | EVP, Corp Strategy & CCO | 421,875 0.0656% | $4.64 | $1.96M | -22.72% | |
| 2024-06-10 | Sale | Feller Faye | EVP, Chief Medical Officer | 287,900 0.0446% | $4.63 | $1.33M | -22.72% | |
| 2024-06-04 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 600,000 0.1014% | $4.00 | $2.4M | -1.25% | |
| 2024-05-15 | Sale | LAWLIS V BRYAN | director | 35,000 0.0057% | $3.75 | $131,250 | +1.28% | |
| 2023-08-24 | O'Farrell Elizabeth G. | director | 13,186 0.0022% | $2.28 | $30,064 | -0.43% | ||
| 2023-05-11 | Sale | LAWLIS V BRYAN | director | 35,000 0.0067% | $3.00 | $105,000 | -20.42% | |
| 2023-05-01 | Sale | Molineaux Susan | director | 35,000 0.0062% | $2.48 | $86,800 | -10.16% | |
| 2023-02-10 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,668 0.0818% | $3.00 | $1.34M | -23.26% | |
| 2023-02-09 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,666 0.0826% | $3.03 | $1.35M | -23.26% | |
| 2023-02-09 | Sale | GRETHLEIN ANDREW J | EVP, Chief Operating Officer | 384,719 0.0711% | $3.03 | $1.17M | -23.26% | |
| 2023-02-08 | Sale | Bloom Olivia Kyusuk | EVP, Chief Financial Officer | 400,000 0.0742% | $3.08 | $1.23M | -23.61% | |
| 2023-02-08 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,666 0.0828% | $3.08 | $1.38M | -23.61% | |
| 2020-08-21 | O'Farrell Elizabeth G. | director | 17,441 0.0056% | $1.73 | $30,173 | 0.00% | ||
| 2020-01-10 | O'Farrell Elizabeth G. | director | 6,000 0.0029% | $1.34 | $8,056 | +23.36% |
| KILEY THOMAS | director | 314059 0.0489% | $292,074.87 | 2 | 0 | <0.0001% |
| BRADBURY DANIEL | director | 142776 0.0222% | $132,781.68 | 1 | 0 | +72.94% |
| Ziegler James | EVP, Chief Commercial Officer | 100000 0.0156% | $93,000.00 | 1 | 0 | <0.0001% |
| Samuels Scott Alan | EVP, Chief Legal Officer | 26682 0.0042% | $24,814.26 | 1 | 0 | <0.0001% |
| O'Farrell Elizabeth G. | director | 26220 0.0041% | $24,384.60 | 3 | 0 | +7.64% |
| LAWLIS V BRYAN | director | 13300 0.0021% | $12,369.00 | 1 | 2 | +16.95% |
| SCARLETT JOHN A | Chairman, President and CEO | 12500 0.0019% | $11,625.00 | 3 | 4 | <0.0001% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
$1,344,238 | 38 | 23.07% | $639.18M |
| Increased Positions | 96 | +29% | 33M | +6.42% |
| Decreased Positions | 131 | -39.58% | 60M | -11.87% |
| New Positions | 30 | New | 3M | New |
| Sold Out Positions | 32 | Sold Out | 8M | Sold Out |
| Total Postitions | 296 | -10.57% | 480M | -5.45% |
| Ra Capital Management, L.P. | $79,701.00 | 9.46% | 60.38M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $61,520.00 | 7.31% | 46.61M | -3M | -6.83% | 2025-09-30 |
| Deep Track Capital, Lp | $54,247.00 | 6.44% | 41.1M | -2M | -4.43% | 2025-09-30 |
| Vanguard Group Inc | $45,439.00 | 5.4% | 34.42M | -1M | -3.34% | 2025-09-30 |
| Vivo Capital, Llc | $35,937.00 | 4.27% | 27.23M | 0 | 0% | 2025-09-30 |
| State Street Corp | $35,137.00 | 4.17% | 26.62M | +3M | +12.64% | 2025-09-30 |
| Goldman Sachs Group Inc | $28,126.00 | 3.34% | 21.31M | +11M | +117.08% | 2025-09-30 |
| Soleus Capital Management, L.P. | $22,823.00 | 2.71% | 17.29M | +1M | +7.13% | 2025-09-30 |
| Vestal Point Capital, Lp | $22,737.00 | 2.7% | 17.23M | -7M | -27.55% | 2025-09-30 |
| Citadel Advisors Llc | $20,731.00 | 2.46% | 15.71M | +4M | +30.48% | 2025-09-30 |